---
title: "Foundayo (Orforglipron): The Oral GLP-1 Pill Approved in the US - When Is It Coming to the UK?"
description: "Foundayo (orforglipron) is now FDA-approved in the US. Here's what UK women need to know: how it works, how it compares to Mounjaro, and a realistic MHRA timeline."
image: https://blog.tribelle.co.uk/hubfs/Home%20Testing%20Blog%20(3)-1.png
---
[Skip to content](https://blog.tribelle.co.uk/orforglipron-weight-loss-pill-uk#main-content)
[Homepage](https://tribelle.co.uk/)
- [Treatments](https://tribelle.co.uk/treatments)
- [How TribElle Works](https://pharmacy.tribelle.co.uk?hsLang=en)
- [About Us](https://pharmacy.tribelle.co.uk/about-us-tribelle-uk?hsLang=en)
- Education
- [Women's Health Through the Decades](https://pharmacy.tribelle.co.uk/life-stages?hsLang=en)
- Blog
- [Blog English](https://blog.tribelle.co.uk)
- [Blog Punjabi](https://blog.tribelle.co.uk/pa?hsLang=en)
- [Blog Telugu](https://blog.tribelle.co.uk/te?hsLang=en)
- [Blog Hindi](https://blog.tribelle.co.uk/hi-in?hsLang=en)
- [Events](https://pharmacy.tribelle.co.uk/events?hsLang=en)
- [FAQs](https://pharmacy.tribelle.co.uk/frequently-asked-questions?hsLang=en)
[Sign in](https://tribelle.co.uk/profile)
- [Treatments](https://tribelle.co.uk/treatments)
- [How TribElle Works](https://pharmacy.tribelle.co.uk?hsLang=en)
- [About Us](https://pharmacy.tribelle.co.uk/about-us-tribelle-uk?hsLang=en)
- Education
- [Women's Health Through the Decades](https://pharmacy.tribelle.co.uk/life-stages?hsLang=en)
- Blog
- [Blog English](https://blog.tribelle.co.uk)
- [Blog Punjabi](https://blog.tribelle.co.uk/pa?hsLang=en)
- [Blog Telugu](https://blog.tribelle.co.uk/te?hsLang=en)
- [Blog Hindi](https://blog.tribelle.co.uk/hi-in?hsLang=en)
- [Events](https://pharmacy.tribelle.co.uk/events?hsLang=en)
- [FAQs](https://pharmacy.tribelle.co.uk/frequently-asked-questions?hsLang=en)
[Sign in](https://tribelle.co.uk/profile)
-1.png?width=1800&height=1000&name=Home%20Testing%20Blog%20(3)-1.png)
Oral GLP-1 obesity treatment Orforglipron
# Foundayo (Orforglipron): The Oral GLP-1 Pill Approved in the US - When Is It Coming to the UK?
.png?width=48&height=48&name=Untitled%20design%20(23).png)
TribElle Clinical Team
February 21, 2026
**Breaking news update!**
- **Foundayo (orforglipron) was FDA approved in the US on 1 April 2026**
- **It is now available in US pharmacies and via LillyDirect**
- **It is not yet approved by the MHRA in the UK**
- **MHRA submission is underway; UK availability is estimated late 2026 to 2027 for private, 2027+ for NHS**
Obesity affects nearly **1 in 4 UK adults** and is one of the country's fastest-growing health challenges. GLP-1 therapies like Wegovy and Mounjaro have transformed weight-loss care, but they're injectable, and that's not ideal for everyone. Needles, cold storage, injection anxiety, for many people, the barriers are real.
Meet Orforglipron.
A once-daily oral pill showing real promise as an alternative to injectable GLP-1s.
💊 Once-Daily Oral Pill 🔬 Phase 3 Trials UK Relevant ⏳ Expected 2026
## What UK-Relevant Trials Show
### Phase 3 ATTAIN-1: Obesity Without Diabetes
The ATTAIN-MAINTAIN trial, which enrolled over 4,500 people across the full ATTAIN programme, tested whether people who had already lost weight on injectable GLP-1s could switch to oral orforglipron for long-term maintenance.
Participants who had reached a weight plateau on injectable Wegovy or Mounjaro were re-randomised - this is a hugely relevant finding for UK women already on injectables who are watching this space.
At 72 weeks, participants taking the highest daily dose lost an average of:
12.4%
of their body weight (~12.4 kg / 27.3 lbs)
vs just 0.9% for placebo
~60%
lost at least 10% of body weight
~40%
lost 15% or more
Participants also saw improvements in cardiovascular risk markers, including cholesterol and blood pressure, suggesting clinically meaningful effects beyond weight loss alone.
### Phase 2 Evidence: The NEJM Data
Earlier Phase 2 data published in *The New England Journal of Medicine* found orforglipron achieved **8.6%–14.7% average weight loss over 36 weeks**, significantly outperforming placebo (~2%).
The trial also showed dose-dependent effects on waist circumference and meaningful reductions in BMI and metabolic risk factors, paving the way for the full Phase 3 programme.
## The US launch - what it tells us
- FDA approved 1 April 2026 under the brand name Foundayo
- Available via LillyDirect, telehealth providers and US retail pharmacies, with prescriptions accepted immediately from 6 April[PR Newswire](https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html)
- Eligible people with commercial insurance in the US may pay as little as $25 per month; self-pay starts at $149 per month for the lowest dose. This is useful us in the UK readers thinking about what pricing might look like,[PR Newswire](https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html)
- this is the first small-molecule oral GLP-1 for weight loss to reach the market anywhere in the world!
## Side Effects & Practical Considerations
Orforglipron is designed to be taken once daily **without fasting or fluid restrictions,** which can be easier for many patients than some oral GLP-1 options that require specific timing with meals.
The most commonly reported side effects are gastrointestinal, typically during dose escalation:
🤢 Nausea
🚽 Diarrhoea
😔 Vomiting
These are consistent with the GLP-1 class overall; severity varies by dose and individual tolerance.
Regulatory Status
| FDA approval (US) | Approved 1 April 2026, brand name Foundayo |
| --- | --- |
| MHRA submission (UK) | Eli Lilly has confirmed it has submitted orforglipron for regulatory approval in more than 40 countries, including the UK |
| MHRA review | Mid to late 2026: MHRA regulatory review ongoing |
| Private UK availability | Late 2026 to 2027 if MHRA approval is secured |
| NHS availability | Not expected before 2027 at the earliest, subject to a separate NICE health technology assessment |
Any UK website currently claiming to sell orforglipron is not operating legally.
**How does Foundayo compare to what's available now in the UK?**
- Foundayo vs Mounjaro: both Eli Lilly, but Mounjaro is injectable + dual GIP/GLP-1 vs Foundayo's oral GLP-1 only; Mounjaro shows higher average weight loss (~20% vs ~12%)
- Foundayo vs Wegovy: both GLP-1 only; Wegovy injectable; the oral Wegovy pill (oral semaglutide) is expected to reach the UK sooner, with approval anticipated in late 2026 - if you want an oral GLP-1 option as soon as possible, the Wegovy pill is likely to be the first available in the UK
- While waiting for Foundayo, Mounjaro and Wegovy are available now through GPhC-registered pharmacies, including TribElle
## Why This Matters for the UK
💉
A Pill Could Increase Accessibility
Injectable GLP-1s are proven, but needle aversion, storage requirements, and costs create real barriers. An oral alternative could be easier to integrate into everyday life.
🏥
NHS & Private Prescribing Options
If approved, orforglipron may join the UK's obesity treatment toolkit alongside Mounjaro, Wegovy and Saxenda, giving clinicians more tailored options for their patients.
📊
Public Health Impact
Given the link between obesity and type 2 diabetes, heart disease, and other chronic conditions, more accessible therapies with strong efficacy could meaningfully reduce the long-term burden on the NHS.
## FAQs About Orforglipron in the UK
What is Foundayo?
The US brand name for orforglipron, an oral once-daily GLP-1 pill for weight loss, approved by the FDA on 1 April 2026
Is orforglipron available in the UK?
Not yet. MHRA review is underway; realistic UK availability is late 2026 for private prescribing, 2027+ for NHS
How does orforglipron compare to Mounjaro?
Both are from Eli Lilly. Mounjaro is injectable and targets both GLP-1 and GIP receptors with higher average weight loss. Orforglipron is oral, targets GLP-1 only, and showed around 12.4% average weight loss at the highest dose
Can I buy orforglipron in the UK now?
No. It is not licensed in the UK. Any UK site claiming to sell it is not operating legally
Can I buy orforglipron in the UK now?
No - this is one of its key advantages. It can be taken any time of day without food or water restrictions
What can I take now while waiting?
Mounjaro and Wegovy are both MHRA-approved and available now through regulated pharmacies
Who should not take orforglipron?
Anyone with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 should not take it
Orforglipron could change what weight management looks like for millions.
**we're a GPhC-registered pharmacy and we'll be among the first to offer Foundayo once MHRA approval comes through.**
### Your Tribe Is Here
We're building a bigger, stronger tribe for women, a space where you're seen, heard, and supported in navigating your health journey.
Because every woman deserves healthcare that sees her, hears her, and heals her.
🌱
Explore treatments
### Explore treatment types that might suit you
GLP-1 injections, expert clinical support and a plan built around your body.
[See weight loss treatments →](https://pages.tribelle.co.uk/wl-treatments?hsLang=en)
[Or browse all TribElle treatments →](https://tribelle.co.uk/treatments)
Join the conversation
### You don't have to go through this alone
| 👥 Hormonal Migraine Support UK A community for women navigating hormone-related migraines Join group |
| --- |
| 💛 TribElle Weight Management Support Connect with other women on their weight management journey Join group |
## Share this post
[mailto:https%3A%2F%2Fblog.tribelle.co.uk%2Forforglipron-weight-loss-pill-uk](mailto:https%3A%2F%2Fblog.tribelle.co.uk%2Forforglipron-weight-loss-pill-uk)
## Keep reading
### [ GLP1s The Complete GLP1 Guide](https://blog.tribelle.co.uk/mounjaro-vs-wegovy-weight-loss-medications-guide?hsLang=en)
### [Top 7 Supplements for PMOS Symptoms in 2026](https://blog.tribelle.co.uk/top-7-supplements-for-pmos-symptoms-in-2026?hsLang=en)
Information
- [How TribElle works](https://pages.tribelle.co.uk/?hsLang=en)
- [FAQs](https://pharmacy.tribelle.co.uk/frequently-asked-questions?hsLang=en)
- [NHS](https://nhspharmacy.tribelle.co.uk/home?hsLang=en)
- [Blog](https://blog.tribelle.co.uk/)
- [Events](https://pages.tribelle.co.uk/events?hsLang=en)
- [About Us](https://pharmacy.tribelle.co.uk/about-us-tribelle-uk?hsLang=en)
- [Terms & Conditions](https://pages.tribelle.co.uk/terms-and-conditions?hsLang=en)
- [Privacy & Policy](https://tribelle.co.uk/privacy-policy)
Treatments
- [Weight Loss](https://tribelle.co.uk/treatments/injectable-weight-loss)
- [Menopause Management](https://tribelle.co.uk/treatments/hrt)
- [Migraine Relief](https://pharmacy.tribelle.co.uk/migraines?hsLang=en)
- [See all treatments](https://tribelle.co.uk/treatments)
Need some help?
- [Contact us](https://tribelle.co.uk/contact-us)
- Want to speak to a human being:
[0207 362 4107](tel:+442073624107)
- General Pharmaceutical Council Registered (9012688)
- Superintendent pharmacist – J Boora (2047130)
- Company Number – 16128081
- DUNS Number – 232728742
[](https://www.legitscript.com/websites/?checker_keywords=tribelle.co.uk) 
Privacy Policy · Legal · © 2026. All rights reserved.
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "TribElle Clinical Team",
"url" : "https://blog.tribelle.co.uk/author/tribelleclinicalteam"
},
"dateModified" : "2026-07-07T16:49:12.894Z",
"datePublished" : "2026-02-21T10:59:59.000Z",
"headline" : "Foundayo (Orforglipron): The Oral GLP-1 Pill Approved in the US - When Is It Coming to the UK?",
"image" : [ "https://blog.tribelle.co.uk/hubfs/Home%20Testing%20Blog%20(3)-1.png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.tribelle.co.uk/orforglipron-weight-loss-pill-uk",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.tribelle.co.uk/hubfs/Logo-1.png"
}
}
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "TribElle Clinical Team"
},
"dateModified" : "2026-07-07T16:49:12+0000",
"datePublished" : "2026-02-21T10:59:59+0000",
"description" : "Foundayo (orforglipron) is now FDA-approved in the US. Here's what UK women need to know: how it works, how it compares to Mounjaro, and a realistic MHRA timeline.",
"headline" : "Foundayo (Orforglipron): The Oral GLP-1 Pill Approved in the US - When Is It Coming to the UK?",
"image" : "https://48505236.fs1.hubspotusercontent-na1.net/hubfs/48505236/Home%20Testing%20Blog%20%283%29-1.png",
"mainEntityOfPage" : {
"@id" : "https://blog.tribelle.co.uk/orforglipron-weight-loss-pill-uk",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://tribelle.co.uk/assets/tribelle-9L69yOUF.svg"
},
"name" : "TribElle"
}
}
```